ALC News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AL

Mkt Cap

$31.99B

Volume

1.35M

Next Earnings

November 10th

Loading chart

AL

ALCAlcon Inc. Ordinary Shares

ALC

Pay with—

Available Balance0.00

AL

Mkt Cap

$32.18B

Volume

1.35M

Next Earnings

November 10th

Chart Financials Earnings News About Dividends Insider Filings

Wellcome Leap Appoints John Young and Thomas Glanzmann to Board of DirectorsWellcome Leap, a nonprofit founded by the Wellcome Trust to accelerate health breakthroughs, announced that John Young (former Pfizer Chief Business Officer) and Thomas Glanzmann (former Grifols CEO) have joined its Board of Directors. Both bring decades of experience in global healthcare leadership, pharmaceutical operations, and business development.GlobeNewswire Inc. · Sep 9, 2026

Bill Ackman’s Pershing Square Just Bought Netflix and 5 Other Stocks. Here’s What Investors Need to Know.Bill Ackman's Pershing Square deployed 85% of its $5 billion capital raise by purchasing Netflix, Visa, Mastercard, S&P Global, Intercontinental Exchange, and Alcon. The fund targeted stocks that have sold off due to AI disruption concerns, believing these companies have competitive advantages that will allow them to thrive despite AI-related headwinds.The Motley Fool · Aug 13, 2026

Ophthalmology Devices Market Report Released, Includes Profiles of EssilorLuxottica, Alcon, Bausch + Lomb, and 20 OthersThe global ophthalmology devices market is projected to grow from $56.61 billion in 2025 to $99.22 billion by 2030, with a CAGR of 11.9%. Key growth drivers include rising demand for minimally invasive surgeries, an aging population, increased eye disorders, and innovation in precision surgical tools. Leading companies include EssilorLuxottica, Alcon, Bausch + Lomb, and HOYA Corporation, with North America currently leading the market while Asia-Pacific shows rapid growth potential.GlobeNewswire Inc. · Jul 13, 2026

Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?Abbott Laboratories and Glaukos represent two contrasting healthcare investment strategies: Abbott offers stability through diversification, strong profitability, and recent acquisitions like Exact Sciences, while Glaukos provides high-growth potential in specialized ophthalmic treatments with innovative products like iDose and Epioxa. Abbott trades at a lower valuation multiple but faces integration challenges and legal risks, while Glaukos shows rapid 32% revenue growth but remains unprofitable and dependent on a single manufacturing location.The Motley Fool · Jul 8, 2026

National Advertising Division Finds Certain ACUVUE® Oasys Max Claim Supported; Recommends Modification or Discontinuation of OthersThe National Advertising Division ruled that Johnson & Johnson Vision Care's claim 'MAX comfort. MAX clarity.' for ACUVUE® Oasys Max 1-Day contact lenses is supported when compared to Oasys 1-Day. However, NAD recommended discontinuation or modification of superiority claims versus DAILIES TOTAL1® and '2X' comparative claims, finding insufficient evidence for these assertions. JJVC agreed to comply with the recommendations.GlobeNewswire Inc. · Apr 20, 2026

LENSAR Stock Plunges—Alcon Scraps Merger After Prolonged Regulatory ReviewAlcon has terminated its merger agreement with LENSAR, a laser solutions company, after prolonged regulatory review by the Federal Trade Commission made the deal unattractive. The acquisition, originally agreed upon in March 2025 at $14.00 per share, faced extended delays and opposition. LENSAR shares plunged 25.44% in premarket trading to $7.65, hitting a new 52-week low.Benzinga · Mar 17, 2026

2026 DallasCISO ORBIE Awards Recognize Top Security ExecutivesDallasCISO held its 2026 ORBIE Awards ceremony recognizing seven leading CISOs for exceptional cybersecurity leadership and business transformation. Award winners included executives from Alcon, Infor, Sammons Financial Group, National Veterinary Associates, DFW International Airport, MRO Corp, and Okta. The event brought together over 250 industry leaders and was supported by major technology partners including Google Cloud, Halcyon, and others.GlobeNewswire Inc. · Feb 26, 2026

LENSAR® Provides Update on Pending Acquisition by AlconLENSAR, Inc. announced that its pending acquisition by Alcon Research, LLC remains under FTC review following a Second Request for Additional Information. The company expects to close the transaction in the first half of 2026, subject to regulatory approval and satisfaction of closing conditions.GlobeNewswire Inc. · Feb 25, 2026

Global Ophthalmic Drugs Market Estimated at US$41.88 Billion in 2026; Projected to Grow at 7.9% CAGR Through 2036The global ophthalmic drugs market is projected to reach US$41.88 billion in 2026 and grow at 7.9% CAGR through 2036, driven by biologic innovation, anti-VEGF therapies, AI-enabled diagnostics, and long-acting drug delivery systems. Key developments include expanded digital distribution channels and sustained-release implants reducing treatment burden for retinal disorders.GlobeNewswire Inc. · Feb 25, 2026

FDA Expands Approval For Staar Surgical's Popular Implantable LensThe FDA approved an expanded age indication for Staar Surgical's EVO/EVO+ Visian Implantable Collamer Lenses, extending eligibility from ages 21-45 to 21-60 years old. This could add nearly 8 million refractive patients to the market. The approval is based on three-year clinical trial data showing strong safety profiles. Despite the positive news, the stock trades 9.8% below its 20-day moving average with bearish technical indicators, though RSI suggests oversold conditions.Benzinga · Feb 18, 2026

to start trading

AL

ALCAlcon Inc. Ordinary Shares

ALC

Pay with—

Available Balance0.00

Your PositionYou don't own any ALC yet.

Related Tickers

Earnings

Dividends

Last · May 6Annual

Amount$0.36

Yield1.08%

Annual$0.72